Zanubrutinib is a targeted therapeutic agent (a Bruton’s tyrosine kinase [BTK] inhibitor) used to treat certain types of lymphoma. It must be administered strictly under medical supervision. Key safety concerns include infection risk, bleeding tendency, monitoring of hepatic and renal function, and drug–drug interactions. Detailed precautions are outlined below:
I. Pre‑administration Precautions
Follow Prescribing Instructions
Use zanubrutinib at the dosage and for the treatment duration prescribed by your physician. Do not adjust the dose or discontinue treatment on your own.
Disclose Full Medical History
Inform your doctor if you have active infections, bleeding disorders, hepatic or renal impairment, or cardiac conditions.
Consult your physician if you have recently received a vaccination or plan to undergo vaccination.
II. Precautions During Treatment
Infection Prevention
Treatment may increase the risk of bacterial, viral, or fungal infections. Seek immediate medical attention if you develop symptoms such as fever or cough.
Avoid contact with individuals with infectious diseases and maintain strict personal hygiene.
Bleeding Risk
May cause bleeding events (e.g., epistaxis, ecchymosis); in severe cases, visceral hemorrhage may occur. Monitor closely for signs of bleeding.
Avoid concomitant use of anticoagulants (e.g., aspirin) or invasive procedures (e.g., dental extraction).
Complete Blood Count Monitoring
Undergo regular blood cell count tests to monitor for leukopenia, thrombocytopenia, and other hematologic abnormalities.
Hepatic and Renal Function Monitoring
Regularly assess liver enzyme and renal function parameters during treatment.
III. Management of Adverse Reactions
Common Reactions
Adverse events such as diarrhea, rash, and fatigue are usually mild to moderate. Contact your physician if these symptoms persist or worsen.
Severe Reactions
Discontinue the drug immediately and seek emergency care for dyspnea or severe allergic reactions (e.g., rash accompanied by edema).
Although rare, cardiac arrhythmias (e.g., atrial fibrillation) may occur. Be alert for symptoms such as palpitations or dizziness.
IV. Precautions for Special Populations
Patients with Hepatic or Renal Impairment
Dose adjustment may be required. Strictly follow the guidance of your treating physician.
Pregnant and Lactating Women
Zanubrutinib has the potential to cause fetal harm. Highly effective contraception must be used during treatment, and breastfeeding must be discontinued.
V. Drug Interactions
Concomitant Medications
Agents such as antifungals and antiepileptics may alter the metabolism of zanubrutinib. Inform your doctor of all medications you are taking (including dietary supplements).
Food Interactions
Avoid concomitant consumption with grapefruit or grapefruit‑containing products, as this may potentiate the side effects of zanubrutinib.
VI. Storage and Missed Dose Management
Storage Conditions
Store in a dry place, protected from light, at temperatures below 25°C.
Missed Dose
If a dose is missed and remembered on the same day, take it as soon as possible. Do not make up for the missed dose on the following day, and never take a double dose to compensate.
Note: Zanubrutinib is a prescription medication. Regular follow‑up visits are required during treatment, and your physician will adjust the regimen based on therapeutic response and adverse reactions. Seek prompt medical attention if any abnormal symptoms occur.
